Completed
A Comparative Study of the Antiviral Effect of a Two or Three Times Daily Triple-Drug Regimen (Indinavir, Nelfinavir or Saquinavir [SGC], Lamivudine plus Zidovudine or Stavudine) against a Once Daily Regimen including Adefovir, Didanosine, Lamivudine and Nevirapine: Trial results
Learn MoreCompleted
A Pharmacokinetic Assessment of Intermittent Rifabutin Dosing Regimens in the Setting of Protease Inhibitor Therapy with a Combination of Ritonavir and Saquinavir in HIV-Infected Patients: Trial results
Learn MoreCompleted
A Phase III Trial to Compare the Safety and Antiviral Efficacy of 141W94 with Indinavir in Combination with Standard Nucleoside Reverse Transcriptase Inhibitor (NRTI) Therapy in NRTI-Experienced, Protease Inhibitor (PI)-Naïve, HIV-1 Infected Patients. (Protocol PROA/B3006 [569/050]): Trial results
Learn MoreCompleted
A Multicentre, Randomized, Double-Blind, Phase II Study to Evaluate the Safety, Tolerance and Efficacy of Multiple Doses of SCH 56592 versus Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients: Trial results
Learn MoreCompleted
A Phase III, Randomised, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IND in HIV-1 Infected, Antiretroviral Therapy-Naïve Subjects: Trial results
Learn MoreCompleted
A Phase III, Double-Blind, Placebo-Controlled, Multicentre Study to Determine the Effectiveness and Tolerability of the Combination of DMP 266 and Indinavir versus Indinavir in HIV-Infected Patients Receiving Nucleoside Analogue (NRTI) Therapy: Trial results
Learn MoreCompleted
A Phase III, Multicentre, Randomized, Open-Label Study to Compare Antiretroviral Activity and Tolerability of Three Combination Regimens (DMP 266 plus Indinavir, DMP 266 plus Zidovudine plus Lamivudine, Indinavir plus Zidovudine plus Lamivudine) in HIV-Infected Patients
Learn MoreCompleted
A randomized, open-label, phase III, international study of subcutaneous recombinant IL-2 (Proleukin®) in patients with HIV-1 infection and CD4+ cell counts > 300 cells/mm3 (Evaluation of subcutaneous Proleukin in a randomized international trial; ESPRIT): Trial results
Learn MoreCompleted
A Randomized Trial of the Efficacy and Safety of Nelfinavir vs. Ritonavir added to Background Antiretroviral Nucleoside Therapy in HIV-Infected Individuals with CD4+ Cell Counts < 100 mm3: Trial results
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
